Page last updated: 2024-08-21

alpha-aminopyridine and enasidenib

alpha-aminopyridine has been researched along with enasidenib in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	38 (52.78)	24.3611
2020's	34 (47.22)	2.80

Authors

Authors	Studies
Kiyoi, H	1
Mullard, A	1
Artin, E; Bawa, O; Bernard, OA; Biller, SA; Broutin, S; Chen, Y; Choe, S; Cianchetta, G; Dang, L; David, MD; de Botton, S; DeLaBarre, B; Dorsch, M; Fang, C; Gross, S; Jiang, F; Jin, L; Jin, S; Konteatis, Z; Liu, W; Marteyn, BS; Nagaraja, R; Opolon, P; Paci, A; Padyana, A; Penard-Lacronique, V; Pilichowska, M; Quivoron, C; Saada, V; Salituro, FG; Saunders, JO; Silverman, L; Straley, K; Su, SM; Tobin, E; Travins, J; Wang, F; Wei, W; Xu, Y; Yang, H; Yen, K	1
Garrett-Bakelman, FE; Glass, J; Gliser, C; Intlekofer, AM; Knapp, K; Levine, RL; Mason, CE; Melnick, A; Meydan, C; Nazir, A; Shank, K; Shih, AH; Stein, EM; Straley, K; Thompson, CB; Travins, J; Ward, PS; Yen, K	1
Cole, R; Gregory, GP; Johnstone, RW; Kats, LM; Li, J; Nagaraja, R; Rogers, AJ; Vervoort, SJ; Vidacs, E; Yen, KE	1
Majeti, R; Thomas, D	1
DiNardo, CD; Medeiros, BC; Stone, RM	1
Sheridan, C	1
Kim, ES	1
Garber, K	1
Tiong, IS; Wei, AH	2
Haroun, F; Lap, CJ; Nassereddine, S; Tabbara, I	1
Chen, Y; Hu, M; Li, Z; Wang, F; Yan, G; Zhang, T; Zhao, L; Zhao, Y	1
Stein, EM	2
Stone, RM; Yogarajah, M	1
Atsriku, C; Fan, B; Hoffmann, M; Li, Y; Reyes, J; Surapaneni, S; Tong, Z; Wang, X; Yang, H; Yerramilli, U	1
Patel, SA	1
Attar, EC; de Botton, S; DiNardo, CD; Fathi, AT; Gupta, I; Kenvin, L; Kline, I; Stein, EM	1
DiNardo, C	1
Dugan, J; Pollyea, D	1
Roboz, GJ	1
Agresta, S; Alsafadi, S; Amatangelo, M; Bernard, OA; David, MD; De Botton, S; Heiblig, M; Kennedy, A; Levine, R; MacBeth, K; Metzner, M; Penard-Lacronique, V; Peniket, A; Quek, L; Quivoron, C; Saada, V; Shih, A; Stein, E; Stoilova, B; Thakurta, A; Vassiliou, GS; Vijayabaskar, MS; Vyas, P; Willekens, C; Yen, K	1
Killock, D	1
Sweet, K; Talati, C	1
Coombs, CC; Galeotti, J	1
Bansal, P; Bhatia, R; Dogra, R; Rawal, RK; Shankar, R	1
Chen, J; Gomez, D; Li, Y; Liu, L; Palmisano, M; Tong, Z; Zhou, S	1
Hoffmann, M; Surapaneni, S; Tong, Z; Yao, S; Yerramilli, U; Young, JD	1
Dittakavi, S; Jat, RK; Mullangi, R	1
Bullinger, L	1
Aschenbrenner, DS	1
Agresta, SV; Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; See, WL; Stein, AS; Stein, EM; Tallman, MS; Tosolini, A; Xu, Q	1
DiNardo, C; Guerra, VA; Konopleva, M	1
Estey, EH; Percival, MM	1
Adhikary, R; Ali, MA; Khandelwal, R; Nayarisseri, A; Pancholi, R; Singh, SK; Srinitha, S; Sweta, J; Vuree, S	1
Dittakavi, S; Hallur, G; Kiran, V; Mullangi, R; Purra, BR; Zakkula, A	1
DiNardo, CD; Wei, AH	1
Azizi, A; Dutta, R; Gars, E; Kaur, S; Köhnke, T; Linde, M; Majeti, R; Nakauchi, Y; Narla, A; Stafford, M; Thomas, D; Yin, R; Zhang, TY	1
Santini, V	1
Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Fathi, AT; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; Roboz, GJ; See, WL; Sekeres, MA; Stein, EM; Stone, RM; Tallman, MS; Tosolini, A; Xu, Q	1
Artz, AS; Cahill, K; Charnot-Katsikas, A; Gurbuxani, S; Kosuri, S; Larson, RA; Liu, H; Odenike, O; Patel, AA; Segal, J; Stock, W; Thirman, M	1
Beaver, JA; Charlab, R; de Claro, RA; Deisseroth, A; Dorff, SE; Farrell, AT; Kazandjian, D; Mulkey, F; Norsworthy, KJ; Pazdur, R; Przepiorka, D; Scott, EC; Sridhara, R; Ward, AF	1
Zeidner, JF	1
Naoe, T	1
Duong, VH; Kallen, ME; Koka, R; Sanchez-Petitto, G; Singh, Z; Yared, JA; Zaman, QU	1
Arber, DA; Erba, HP	1
Bae, SH; Cheong, JW; Jeung, HK; Kim, Y; Lee, JI; Min, YH; Song, J	1
Cardinali, V; Cerchione, C; Falini, B; Martelli, MP; Martinelli, G; Martino, G	1
Cerchione, C; Martinelli, G	1
Moore, DC; Muslimani, A; Nelson, V	1
Almon, C; Choe, S; Cooper, M; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Franovic, A; Frattini, MG; Hua, L; Kantarjian, HM; Lersch, F; Löwenberg, B; McCloskey, JK; Mims, AS; Nabhan, S; Odenike, O; Ossenkoppele, GJ; Patel, PA; Pollyea, DA; Pratz, KW; Roshal, M; Savona, MR; Seet, CS; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Wang, H; Winer, ES; Wu, B	1
Baran, N; Bellvert, F; Boet, E; Bories, P; Bosc, C; Broin, N; Carroll, M; Cassan, C; Castellano, R; Castelli, FA; Cazals, G; Chu-Van, E; Cissé, MY; Cognet, G; Collette, Y; Conti, M; DiNardo, CD; Farge, T; Fenaille, F; Fernando, L; Gales, L; Gibon, Y; Gotanègre, M; Hosseini, M; Hucteau, A; Jourdan, F; Kaoma, T; Konopleva, M; Larrue, C; Le Cam, L; Linares, LK; Loric, S; Marszalek, JR; Montersino, C; Mouchel, PL; Nicolay, B; Pancaldi, V; Portais, JC; Poupin, N; Récher, C; Ronseaux, S; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Selak, MA; Stuani, L; Takahashi, K; Turtoi, A; Turtoi, E; Vey, N; Wang, F; Zavoriti, A	1
Avanzino, B; Chopra, VS; DiMartino, JF; Figueroa, ME; MacBeth, KJ; Quek, L; Schwickart, M; See, WL; Tang, L; Zheng, B	1
Andrew Futreal, P; Bhalla, KN; DiNardo, CD; Frattini, M; Furudate, K; Garcia-Manero, G; Gumbs, C; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, M; Little, LD; Liu, G; MacBeth, KJ; Matthews, JA; Morita, K; Patel, KP; Ravandi, F; Song, X; Takahashi, K; Tanaka, T; Thompson, EJ; Wang, F; Wu, B; Yan, Y; Zhang, J	1
Bal, N; Bergl, PA; Bursch, K; Carlson, KS; Hernandez, JR; Khan, M; Roddy, JT	1
Graff, JP; Karnati, T; Lee, D; Omofoye, OA; Shahlaie, K	1
Buhlinger, K; Coombs, CC; Foster, MC; Galeotti, J; Kaiser-Rogers, K; Montgomery, ND; Nichols, A; Ramkissoon, LA; Richardson, DR; Zeidner, JF	1
de Botton, S; Dragani, M	1
Boissel, N; Brandwein, JM; Cameron, C; Chantepie, S; de Botton, S; Frattini, MG; Hunault-Berger, M; Hutton, B; Legrand, O; Marion-Gallois, R; Milkovich, G; Nehme, SA; Pigneux, A; Quesnel, B; Recher, C; Siddiqui, M; Stein, EM; Thomas, X; Tosolini, A; Wang, JJ; Wei, AH	1
Carayannopoulos, L; Cheng, Y; Li, Y; Reyes, J; Tong, Z; Wang, X; Zhou, S	1
Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM	1
Cathelin, S; Chan, SM; Cojocari, D; Leverson, JD; Liu, G; MacBeth, KJ; Narayanaswamy, R; Nicolay, B; Phillips, DC; Ronseaux, S; Sharon, D; Subedi, A	1
Thol, F	1
Alanazi, AM; AlRabiah, H; Bakheit, AH; Hassan, ES; Naglah, AM; Saber Abdelhameed, A	1
Almon, C; Chen, Y; Cooper, M; Fan, B; Hossain, M; Hua, L; Nabhan, S; Yang, H; Yin, F	1
Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H	1
Copher, R; Gajra, A; Hou, Y; Klink, AJ; Knoth, RL; Marshall, L; McBride, A	1
Guo, H; Jin, R; Nie, F; Tang, T; Tang, Y; Wang, Y; Zhou, S	1

Reviews

17 review(s) available for alpha-aminopyridine and enasidenib

Article	Year
Overview: A New Era of Cancer Genome in Myeloid Malignancies. Oncology, 2015, Volume: 89 Suppl 1 Topics: Aminopyridines; Anemia, Aplastic; Antineoplastic Agents; Benzimidazoles; Clonal Evolution; Genome, Human; Hematopoiesis; Histone-Lysine N-Methyltransferase; Humans; Immunosuppressive Agents; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Mutation; Myelodysplastic Syndromes; Triazines	2015
Novel Therapeutics in Acute Myeloid Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume: 37 Topics: Aminopyridines; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Triazines	2017
Enasidenib: First Global Approval. Drugs, 2017, Volume: 77, Issue:15 Topics: Administration, Oral; Aminopyridines; Drug Approval; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines; United States; United States Food and Drug Administration	2017
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood, 2017, 12-07, Volume: 130, Issue:23 Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines	2017
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Annals of hematology, 2017, Volume: 96, Issue:12 Topics: Aminopyridines; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Triazines	2017
A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert review of hematology, 2018, Volume: 11, Issue:2 Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Triazines	2018
Enasidenib for the treatment of acute myeloid leukemia. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:8 Topics: Adult; Aminopyridines; Antineoplastic Agents; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines	2018
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leukemia research, 2018, Volume: 73 Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines	2018
Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia. Anti-cancer agents in medicinal chemistry, 2018, Volume: 18, Issue:14 Topics: Aminopyridines; Antineoplastic Agents; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Recurrence; Triazines	2018
New drugs creating new challenges in acute myeloid leukemia. Genes, chromosomes & cancer, 2019, Volume: 58, Issue:12 Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration	2019
Venetoclax-based therapies for acute myeloid leukemia. Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:2 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines	2019
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. Cancer, 2019, Sep-15, Volume: 125, Issue:18 Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles	2019
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya journal of medical science, 2020, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines	2020
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). American journal of clinical pathology, 2020, 11-04, Volume: 154, Issue:6 Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines	2020
Enasidenib and ivosidenib in AML. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Clinical Trials as Topic; Glutarates; Glycine; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation, Missense; NADP; Pyridines; Syndrome; Triazines	2020
SOHO State of the Art Updates and Next Questions: IDH Inhibition. Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:9 Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Middle Aged; Pyridines; Triazines	2021
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database. Current problems in cardiology, 2022, Volume: 47, Issue:11 Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration	2022

Trials

9 trial(s) available for alpha-aminopyridine and enasidenib

Article	Year
Positive First Trial of Enasidenib for AML. Cancer discovery, 2017, Volume: 7, Issue:8 Topics: Adult; Aged; Aminopyridines; Disease-Free Survival; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Triazines	2017
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Future oncology (London, England), 2018, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Bone Marrow Cells; Cell Differentiation; Disease-Free Survival; Female; GTP Phosphohydrolases; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Mutant Proteins; Mutation; Recurrence; Triazines	2018
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA oncology, 2018, 08-01, Volume: 4, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Syndrome; Triazines	2018
Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects. Pharmacology research & perspectives, 2018, Volume: 6, Issue:6 Topics: Adult; Aminopyridines; Antineoplastic Agents; Area Under Curve; Asian People; Healthy Volunteers; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Neoplasms; Triazines; White People; Young Adult	2018
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia, 2019, Volume: 33, Issue:11 Topics: Aged; Aged, 80 and over; Aminopyridines; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutant Proteins; Mutation; Remission Induction; Treatment Outcome; Triazines	2019
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. The Lancet. Haematology, 2020, Volume: 7, Issue:4 Topics: Aged; Aminopyridines; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperbilirubinemia; Isocitrate Dehydrogenase; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Triazines	2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 04-01, Volume: 137, Issue:13 Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyridines; Treatment Outcome; Triazines; Young Adult	2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. The Lancet. Oncology, 2021, Volume: 22, Issue:11 Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines	2021
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:4 Topics: Adult; Aminopyridines; Antineoplastic Agents; Consolidation Chemotherapy; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines	2022

Other Studies

46 other study(ies) available for alpha-aminopyridine and enasidenib

Article	Year
Cancer metabolism pipeline breaks new ground. Nature reviews. Drug discovery, 2016, Nov-03, Volume: 15, Issue:11 Topics: Aminopyridines; Antineoplastic Agents; Drug Approval; Drug Discovery; Drug Industry; Humans; Metabolic Networks and Pathways; Neoplasms; Triazines	2016
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Cancer discovery, 2017, Volume: 7, Issue:5 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mutation; Triazines; Xenograft Model Antitumor Assays	2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in Cancer discovery, 2017, Volume: 7, Issue:5 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Signal Transduction; Triazines	2017
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia, 2017, Volume: 31, Issue:6 Topics: Aminopyridines; Antineoplastic Agents; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pharmacogenetics; Triazines	2017
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer discovery, 2017, Volume: 7, Issue:5 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines	2017
First new drug approval for AML in 15 years. Nature biotechnology, 2017, 08-08, Volume: 35, Issue:8 Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines	2017
First metabolic oncology inhibitor gets FDA green light, with record price tag. Nature biotechnology, 2017, 10-11, Volume: 35, Issue:10 Topics: Aminopyridines; Drug Approval; Drug Industry; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Triazines; United States; United States Food and Drug Administration	2017
Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Chemical biology & drug design, 2018, Volume: 91, Issue:6 Topics: Aminopyridines; Binding Sites; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Isocitrate Dehydrogenase; Molecular Docking Simulation; Mutation; Protein Structure, Tertiary; Pyridines; Structure-Activity Relationship; Triazines	2018
Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans. Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:2 Topics: Aminopyridines; Animals; Antineoplastic Agents; Bile; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Isocitrate Dehydrogenase; Kidney; Liver; Metabolic Networks and Pathways; Rats; Tandem Mass Spectrometry; Triazines	2019
Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia. JAMA oncology, 2018, 08-01, Volume: 4, Issue:8 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Triazines	2018
In brief: Two new drugs for AML. The Medical letter on drugs and therapeutics, 2018, 03-26, Volume: 60, Issue:1543 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Mutation; Treatment Outcome; Triazines	2018
Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:4 Topics: Aminopyridines; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Multicenter Studies as Topic; Mutation; Prognosis; Recurrence; Research; Treatment Outcome; Triazines	2018
Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:5 Topics: Administration, Oral; Aminopyridines; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Prognosis; Recurrence; Remission Induction; Survival Analysis; Triazines	2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature medicine, 2018, Volume: 24, Issue:8 Topics: Aminopyridines; Cell Differentiation; Clone Cells; Cohort Studies; Hematopoiesis; Humans; Immunophenotyping; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Triazines	2018
Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML. Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:10 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Triazines	2018
Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations. British journal of haematology, 2019, Volume: 184, Issue:4 Topics: Aged; Aminopyridines; Cell Differentiation; Eosinophils; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Splicing Factor U2AF; Triazines	2019
Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:10 Topics: Aminopyridines; Animals; Azacitidine; Cell Line; Humans; Isocitrate Dehydrogenase; Nucleoside Transport Proteins; Triazines; Xenopus laevis	2019
Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study. Biomedical chromatography : BMC, 2019, Volume: 33, Issue:6 Topics: Aminopyridines; Animals; Chromatography, Liquid; Dried Blood Spot Testing; Limit of Detection; Linear Models; Male; Mice; Mice, Inbred BALB C; Reproducibility of Results; Tandem Mass Spectrometry; Triazines	2019
IDH2 inhibition: another piece to the puzzle. Blood, 2019, 02-14, Volume: 133, Issue:7 Topics: Aminopyridines; Humans; Leukemia, Myeloid, Acute; Triazines	2019
FDA Issues Safety Alert for Leukemia Drug. The American journal of nursing, 2019, Volume: 119, Issue:3 Topics: Aminopyridines; Drug Labeling; Humans; Leukemia, Lymphoid; Triazines; United States; United States Food and Drug Administration	2019
Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia. Asian Pacific journal of cancer prevention : APJCP, 2019, 08-01, Volume: 20, Issue:8 Topics: Aminopyridines; High-Throughput Screening Assays; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Models, Molecular; Molecular Docking Simulation; Small Molecule Libraries; Triazines	2019
Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study. Drug research, 2020, Volume: 70, Issue:1 Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Humans; Leukemia, Myeloid, Acute; Male; Mice; Models, Animal; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazines	2020
How I treat acute myeloid leukemia in the era of new drugs. Blood, 2020, 01-09, Volume: 135, Issue:2 Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines	2020
Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2. The Journal of clinical investigation, 2020, 04-01, Volume: 130, Issue:4 Topics: Aminopyridines; Cell Differentiation; Erythroid Cells; Hematopoietic Stem Cells; Humans; Isocitrate Dehydrogenase; Protoporphyrins; Triazines	2020
Enasidenib: a magic bullet for myelodysplastic syndromes? The Lancet. Haematology, 2020, Volume: 7, Issue:4 Topics: Aminopyridines; Humans; Myelodysplastic Syndromes; Triazines	2020
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. British journal of haematology, 2020, Volume: 190, Issue:1 Topics: Aged; Aged, 80 and over; Aminopyridines; Female; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Treatment Outcome; Triazines	2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16 Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines; United States; United States Food and Drug Administration	2020
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16 Topics: Aminopyridines; Cell Differentiation; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines; United States; United States Food and Drug Administration	2020
Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy. Leukemia research, 2020, Volume: 96 Topics: Aminopyridines; Cellulitis; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neutrophils; Prognosis; Skin Diseases; Triazines	2020
All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Yonsei medical journal, 2020, Volume: 61, Issue:9 Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Tretinoin; Triazines	2020
Acute leukemias in 2020: state of the art. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Acute Disease; Aminopyridines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Congresses as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia; Pyridines; Recombinant Fusion Proteins; Staurosporine; Triazines	2020
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. Annals of hematology, 2021, Volume: 100, Issue:12 Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Triazines	2021
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. The Journal of experimental medicine, 2021, 05-03, Volume: 218, Issue:5 Topics: Acute Disease; Aminopyridines; Animals; Cell Line, Tumor; Doxycycline; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Glycine; HL-60 Cells; Humans; Isocitrate Dehydrogenase; Isoenzymes; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Mutation; Oxadiazoles; Oxidative Phosphorylation; Piperidines; Pyridines; Triazines; Xenograft Model Antitumor Assays	2021
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Experimental hematology, 2021, Volume: 98 Topics: Aminopyridines; Azacitidine; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Triazines	2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature communications, 2021, 05-10, Volume: 12, Issue:1 Topics: Aged; Aminopyridines; Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Core Binding Factor Alpha 2 Subunit; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenomics; Evolution, Molecular; Female; Glycine; High-Throughput Nucleotide Sequencing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Multigene Family; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Pyridines; ras Proteins; Repressor Proteins; RNA-Seq; Signal Transduction; Single-Cell Analysis; Stem Cells; Triazines	2021
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML. British journal of haematology, 2021, Volume: 194, Issue:6 Topics: Aged; Aminopyridines; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Ketosis; Leukemia, Myeloid, Acute; Male; Triazines	2021
Intracranial myeloid sarcoma presentation in distant acute myeloid leukemia remission. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 89 Topics: Adult; Aminopyridines; Brain Neoplasms; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Sarcoma, Myeloid; Triazines	2021
Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment. Leukemia & lymphoma, 2021, Volume: 62, Issue:12 Topics: Aminopyridines; Clonal Evolution; Humans; Leukemia, Myeloid, Acute; Philadelphia Chromosome; Triazines	2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer medicine, 2021, Volume: 10, Issue:18 Topics: Adolescent; Adult; Aged; Aminopyridines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; France; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Neoplasm Recurrence, Local; Observational Studies as Topic; Propensity Score; Standard of Care; Treatment Outcome; Triazines; Young Adult	2021
Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Journal of clinical pharmacology, 2022, Volume: 62, Issue:4 Topics: Aged; Aminopyridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Digoxin; Drug Interactions; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Pharmaceutical Preparations; Recurrence; Rosuvastatin Calcium; Triazines	2022
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia, 2022, Volume: 36, Issue:3 Topics: Aminopyridines; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Sulfonamides; Triazines	2022
What to use to treat AML: the role of emerging therapies. Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1 Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines	2021
Spectroscopic and computational investigation of the interaction between the new anticancer agent enasidenib and human serum albumin. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2022, Apr-05, Volume: 270 Topics: Aminopyridines; Antineoplastic Agents; Binding Sites; Circular Dichroism; Humans; Molecular Docking Simulation; Protein Binding; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics; Triazines	2022
Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Leukemia research, 2022, Volume: 122 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines	2022
Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors. Bioorganic chemistry, 2023, Volume: 130 Topics: Aminopyridines; Animals; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Rats; Triazines	2023
IDH2 inhibition in AML. Blood, 2023, 01-12, Volume: 141, Issue:2 Topics: Aged; Aminopyridines; Humans; Leukemia, Myeloid, Acute; Triazines	2023